Sustiva is a brand name for the antiretroviral drug efavirenz used in the treatment of hiv infection. It belongs to the class of non-nucleoside reverse transcriptase inhibitors which block the activity of the reverse transcriptase enzyme. The medication is taken orally and absorbed in the gastrointestinal tract and distributed throughout the body to reach target cells. Once inside infected cells efavirenz binds to a specific site on the reverse transcriptase protein causing a conformational change that prevents viral rna synthesis. This inhibition reduces the production of new viral particles and limits the spread of infection within the host. The drug's active metabolite exerts its effect by stabilizing the enzyme in an inactive conformation thereby enhancing its antiviral potency. Pharmacodynamically the sustained suppression of reverse transcriptase activity contributes to long-term viral load reduction and improved immune function.

Sustiva is an antiretroviral medication used to treat human immunodeficiency virus infection. It belongs to the non-nucleoside reverse transcriptase inhibitor class and works by binding to the reverse transcriptase enzyme. By binding to this enzyme, Sustiva reduces the ability of hiv to convert its rna into dna, thereby slowing viral replication. The drug is metabolized in the liver through the cytochrome p450 system and is eliminated primarily by the kidneys. Its pharmacokinetic profile leads to once-daily dosing because the active metabolite maintains effective concentrations over 24 hours. Clinical studies show that this mechanism provides durable suppression of viral load when combined with other antiretrovirals.

Sustiva may cause central nervous system effects such as dizziness and insomnia. Some individuals report vivid or unusual dreams that can disrupt sleep patterns. Headache and fatigue are frequently reported during the first weeks of treatment. Skin reactions including rash and itching can occur but are usually mild. Elevated liver enzymes have been observed in a subset of patients without clear clinical symptoms. Changes in mood such as depression or anxiety may be experienced by some users. Weight gain and increased cholesterol levels have been documented in long-term studies.

Common side effects of Sustiva include dizziness and vivid dreams. Some users report fatigue and headache. Skin reactions such as rash or itching may develop. Neurological effects can involve depression or anxiety. Metabolic changes like increased cholesterol levels are observed. Liver enzyme elevations can occur in certain individuals. Gastrointestinal disturbances such as nausea are possible. Long-term use may impact lipid profiles.